<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107430">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01710163</url>
  </required_header>
  <id_info>
    <org_study_id>ARIQUELI</org_study_id>
    <nct_id>NCT01710163</nct_id>
  </id_info>
  <brief_title>Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients</brief_title>
  <acronym>ARIQUELI</acronym>
  <official_title>ARIQUELI: Potentiation of Quetiapine Treatment in Bipolar 1 Nonresponders Patients With Lithium or Aripiprazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Bipolar I Disorder refractory treatment
      with Quetiapine monotherapy could be better potentiated with Lithium or Aripiprazole. The
      investigators hypothesized that Lithium or Aripiprazole would provide similar compliance and
      tolerability in maintenance treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The main outcome will be the number of patients that achieve and remain in remission to each treatment at the end of each phase of the study</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bipolar I Disorder</condition>
  <arm_group>
    <arm_group_label>Lithium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Potentiation of previous treatment (Quetiapine monotherapy) with Lithium (0.5 - 0.8 mEq/L)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Potentiation of previous treatment (Quetiapine monotherapy) with Aripiprazole (10 - 15 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium</intervention_name>
    <description>Starting at 300 mg daily, weekly dose will be adjusted according to blood serum level (between 0.5 -0.8mEq/l) according to efficacy and tolerability.</description>
    <arm_group_label>Lithium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Starting at 10 mg daily, dose will be adjusted up to 15 mg daily according to efficacy and tolerability.</description>
    <arm_group_label>Aripiprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Bipolar Disorder, type I, in current episode (manic/hypomanic,
             mixed or depression)

          -  The patient or his (her) legal representative should understand the nature of the
             study and sign the Informed Consent

        Exclusion Criteria:

          -  Schizophrenia or schizoaffective disorder

          -  Mental retardation

          -  Unstable clinical diseases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Alberto Moreno, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Psychiatry, University of São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giovani Missio, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Psychiatry, University of São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giovani Missio</last_name>
    <phone>+ 55 11 2661 6648</phone>
    <email>gmissio@mac.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ricardo Alberto Moreno, MD, PhD</last_name>
    <phone>+ 55 11 2661 6648</phone>
    <email>rmoreno@sti.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Psychiatry, University of São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovani Missio</last_name>
      <phone>+55 11 26616648</phone>
      <email>gmissio@mac.com</email>
    </contact>
    <contact_backup>
      <last_name>Ricardo Alberto Moreno, MD, PhD</last_name>
      <phone>+55 11 26616648</phone>
      <email>rmoreno@sti.com.br</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institute of Psychiatry</name>
      <address>
        <city>São Paulo</city>
        <zip>05403010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missio</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 16, 2012</lastchanged_date>
  <firstreceived_date>July 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Ricardo Alberto Moreno, M.D., Ph.D.</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Lithium Carbonate</keyword>
  <keyword>Lithium</keyword>
  <keyword>Central Nervous System Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Enzyme Inhibitors</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Neurotransmitter Agents</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Antimanic Agents</keyword>
  <keyword>Tranquilizing Agents</keyword>
  <keyword>Central Nervous System Depressants</keyword>
  <keyword>Psychotropic Drugs</keyword>
  <keyword>Sensory System Agents</keyword>
  <keyword>Antipsychotic Agents</keyword>
  <keyword>Antidepressive Agents</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Central Nervous System Agents</mesh_term>
    <mesh_term>Lithium</mesh_term>
    <mesh_term>Quetiapine</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Central Nervous System Depressants</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Tranquilizing Agents</mesh_term>
    <mesh_term>Neurotransmitter Agents</mesh_term>
    <mesh_term>Sensory System Agents</mesh_term>
    <mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
    <mesh_term>Physiological Effects of Drugs</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
